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Introduction {#sec1}
============

Pluripotent stem cells (PSCs) are a powerful tool in a variety of applications ranging from basic studies of development and disease to cell-based therapeutics and regenerative medicine applications ([@bib12], [@bib18], [@bib27]). Human embryonic stem cells (hESCs) ([@bib34]) and induced PSCs (iPSCs) ([@bib31], [@bib38]) are two classes of PSCs that are particularly well-suited for modeling genetic diseases ([@bib25], [@bib30]) as well as serving as a renewable cell source for tissue engineering purposes ([@bib37]). For the potential of PSCs to be realized from basic science to clinical applications, efficient directed differentiation protocols to produce relevant cell types are required. While much work has been done in the area of inducing differentiation of PSCs to various types of somatic cells, methods for generating cells of interest that are simple, chemically defined, and can be adapted and optimized for many cell types are of great interest to a breadth of scientists, engineers, and clinicians.

A number of physical parameters influence hPSC differentiation, including cell density, colony size, and dissociation method, as hPSCs are exquisitely sensitive to paracrine factors from neighboring cells ([@bib10]) and can undergo apoptosis and display karyotypic abnormalities when passaged as single cells ([@bib11], [@bib20]). Advanced microengineering approaches have been used to control cell spacing and colony size, resulting in differentiation platforms amenable to induction of multiple lineages ([@bib2], [@bib16], [@bib19], [@bib21]). Although microfabricated systems can be beneficial for enhancing microenvironmental control over differentiating cells, they are not practical for many laboratories performing fundamental studies. Thus, a simple and broadly applicable platform for controlling microenvironmental conditions that can be utilized in laboratories with a range of specialties to induce differentiation of human PSCs is required.

Here we describe a simple, versatile method to enhance differentiation of multiple mesodermal cells types with a brief pre-differentiation protocol. After 48 h of treatment with moderate concentrations of both BMP4 and Activin A (referred to as BA), a reduction of pluripotency genes and proteins was observed, concurrent with an upregulation of a mesendoderm gene signature. Integration of this 48-h treatment protocol into existing differentiation protocols enhanced the production of chondrocytes and endothelial progenitor cells while reducing neural differentiation capacity. Prolonged exposure of BA-treated cells to basal media without exogenous cues for 14 days resulted in single-cell gene expression profiles consistent with mesoderm and endoderm induction. Teratomas formed from cells pretreated with BA consisted of a higher ratio of mesoderm and endoderm to ectoderm tissue than teratomas formed from untreated cells. Thus, our pre-differentiation system is a simple and effective means for production of mesendoderm progenitors and downstream mesodermal cell lineages.

Results {#sec2}
=======

Single-Cell Seeding in Defined Conditions Produces Robust Mesendoderm Differentiation {#sec2.1}
-------------------------------------------------------------------------------------

The addition of BA to basal medium has been shown to induce differentiation of hPSCs to a primitive streak/mesendoderm phenotype in standard colony-seeded cultures ([@bib33]) and in a micropatterned colony culture system ([@bib21]). We sought to approximate the rigorous spatial control afforded by the micropatterned system and the subsequent control over paracrine signaling effects while circumventing the microcontact printing step necessary to produce micropatterns. We hypothesized that the stricter control of initial cell density in single-cell seeding (SCS) would allow for more uniform and reproducible cell dispersions than colony seeding, which would in turn produce rapid and robust mesendoderm differentiation, similar to micropatterned cultures. To test this hypothesis, we assessed the spatial uniformity of cells seeded by colony and SCS methodologies as well as the downstream differentiation response.

Chemically defined, feeder-free conditions comprising Essential 8 (E8) medium ([@bib7]) and Matrigel-coated dishes were used for hPSC maintenance to optimize hPSC homogeneity. After overnight colony seeding or SCS, H9 hESCs were stained with Hoechst ([Figure 1](#fig1){ref-type="fig"}A), and high-content imaging was used to assess the uniformity of cell seeding. Coefficient of variation (CV) for the number of cells in a 345 × 345-μm grid (equivalent to 25 grids in a 10× image) was calculated and normalized to the CV of an equal number of cells in a simulated random uniform distribution to assess uniformity of seeding. SCS resulted in significantly lower normalized CV than colony seeding across all densities evaluated (p \< 0.0001), indicating a greater degree of spatial uniformity ([Figure 1](#fig1){ref-type="fig"}B). The colony split ratio and SCS density did not have a significant effect on spatial distribution when normalized to a uniform distribution of the same cell number, nor did the SCS density influence overnight cell seeding efficiency (∼60%). Thus, SCS produced a spatially uniform cell distribution at a broad range of seeding densities.Figure 1Single-Cell Seeding and BMP4 and Activin A Treatment Enhance Mesendoderm Differentiation(A) Colony or single-cell seeded (SCS) H9 ESCs were stained with Hoechst and imaged to quantify the spatial positioning of each cell. Scale bar, 200 μm.(B) The spatial uniformity of cells imaged in (A) was assessed by the coefficient of variation (CV) in the number of cells in 345- × 345-μm grids.(C) Schematic depiction of colony and SCS differentiation protocol in E8 (blue), E6 (green), or BA (orange) media.(D) SOX2 staining after 48 h of differentiation in E8, E6, or BA conditions following colony or SCS. Scale bar, 100 μm.(E) Quantification of immunofluorescent staining for OCT4, SOX2, and TBXT after 48 h via high-content imaging. See also [Figure S1](#mmc1){ref-type="supplementary-material"}D.(F) Immunofluorescent staining of TBXT after 48 h of differentiation. Scale bar, 100 μm.(G) Quantification of pluripotency (*OCT4, SOX2*) and mesendoderm (*TBXT*, *MIXL1*, *EOMES, GSC*) gene expression by qPCR analysis. See also [Figure S1](#mmc1){ref-type="supplementary-material"}C.Errors bars represent SEM, n = 3 independent experiments, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001 for (B), (E), and (G).

We then reasoned that the enhanced uniformity of SCS would result in more robust mesendoderm differentiation compared with colony seeding. To test this hypothesis, H9 hESCs were seeded overnight in E8 as colonies (split 1:6) or single cells (1.5 × 10^5^ cells/mL) and allowed to differentiate spontaneously via removal of transforming growth factor β (TGF-β) and fibroblast growth factor (FGF2) from E8 medium to produce a basal media known as E6, or were directed to mesendoderm by addition of BMP4 (40 ng/mL) and Activin A (40 ng/mL) to E6 medium (termed BA; schematically depicted in [Figure 1](#fig1){ref-type="fig"}C). SCS density and BA concentrations were chosen based on empirical testing of a range of densities (data not shown) and concentrations ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B) as well as previous literature ([@bib21]). POU5F1 (OCT4) protein abundance was not significantly different for any combination of treatment (E8, E6, or BA) or seeding method (colony, single cell; [Figure 1](#fig1){ref-type="fig"}E). The percentage of SOX2^+^ cells, which is indicative of both pluripotent and neuroectodermal cells, was significantly higher in SCS E6 cultures compared with SCS E8 and BA ([Figures 1](#fig1){ref-type="fig"}D and 1E). Virtually no expression of SOX2 in SCS BA was observed, suggesting a loss of pluripotency and lack of neuroectoderm differentiation. Expression of Brachyury T (TBXT), a marker of primitive streak and mesendoderm differentiation, was significantly higher in SCS BA cultures compared with SCS E8 and E6 ([Figures 1](#fig1){ref-type="fig"}F and 1E). TBXT expression in E8 and E6 cultures (both colony and SCS) was nearly zero, indicating that spontaneous mesendoderm differentiation was not observed within this time frame. Quantification of cell density based on high-content imaging demonstrated no significant differences between seeding method or medium (E8, E6, or BA) after 48 h, indicating that overall cell yield was not affected by SCS.

Protein expression data were corroborated by population-level qPCR analysis ([Figure 1](#fig1){ref-type="fig"}G). *POU5F1 (OCT4)* expression was largely unchanged among all treatments, with significant differences observed only between E6 (SCS and colony) and colony BA. Expression of *SOX2* transcripts was significantly higher in SCS E6 than all other treatments, in agreement with observed protein expression patterns. The expression of early mesoderm and endoderm markers including TBXT, *MIXL1*, *EOMES*, and *GSC* were also assessed by qPCR. With the exception of *GSC*, which was not significantly upregulated compared with colony BA, all of these markers showed higher expression levels in SCS BA compared with all other treatments. Robust induction of mesendoderm genes was also observed in H1 and H7 hESCs following SCS BA treatment ([Figure S1](#mmc1){ref-type="supplementary-material"}C), as was the expression of TBXT and loss of SOX2 proteins ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Collectively, these data demonstrate that SCS of hPSCs improves the uniformity of spatial dispersion and enhances directed mesendoderm differentiation compared with colony seeding.

BA Treatment Induces Mesendoderm Gene Expression Signatures {#sec2.2}
-----------------------------------------------------------

After ascertaining that SCS could induce robust differentiation of hPSCs, we next sought to assess global transcriptomic changes in cells treated with E8, E6, and BA by RNA sequencing (RNA-seq). A common undifferentiated sample (i.e., t0) as well as 48-h E8, E6, and BA samples were sequenced, along with a 24-h BA time point. E8 and E6 samples clustered separately from the 24- and 48-h BA samples, as indicated by hierarchical clustering ([Figure 2](#fig2){ref-type="fig"}A). Mesendoderm genes were found to be strongly upregulated in the 24- and 48-h time points following BA treatment, including *TBXT*, *EOMES*, *GATA5*, and *MIXL1* ([Figure 2](#fig2){ref-type="fig"}A, red boxes), while neuroectoderm-associated genes were strongly downregulated, including *HES3*, *HTR1A*, *EMX1*, and *LRAT* ([Figure 2](#fig2){ref-type="fig"}A, blue box). Gene ontology (GO) terms associated with ion channel regulation and nervous system development were enriched in the E6 samples, suggesting that E6 medium is permissive of a neuroectoderm fate specification. In contrast, terms associated with general differentiation (embryo development/morphogenesis, tissue/organ morphogenesis) as well as mesoderm-specific differentiation (circulatory/cardiovascular/blood vessel development, heart development) were strongly enriched at both 24 and 48 h in the BA-treated cells. In addition, gene set enrichment analysis (GSEA) of the 48-h BA samples demonstrated that mesendoderm, lateral plate mesoderm, and pre-cartilage condensation gene sets were significantly enriched (p \< 0.0041), while the Neural Ectoderm gene set was not enriched (p = 0.164) ([Figure 2](#fig2){ref-type="fig"}C). Together, GSEA and GO analysis demonstrate that SCS BA treatment induced a gene expression signature indicative of mesendoderm and mesoderm differentiation, while E6 treatment induced early neuroectoderm specification.Figure 2Transcriptomic Analysis of E8, E6, and BA Treatments by RNA-Seq(A) Heatmap of differentially expressed genes between 48-h E8, 48-h E6, and 24- and 48-h BA samples. Heatmaps of selected clusters of genes upregulated in BA (pink box), strongly upregulated in BA (red box) or downregulated in BA samples (blue box) are enlarged.(B) Enriched GO terms for genes upregulated in 48-h E6, 24-h BA, and 48-h BA samples.(C) Gene set enrichment analysis (GSEA) of 48-h BA samples for mesendoderm, lateral plate mesoderm, cartilage condensation, and neural ectoderm gene sets.

Dynamic Transcriptional Networks Regulate Mesendoderm Specification {#sec2.3}
-------------------------------------------------------------------

While transcriptomic analysis after 1 and 2 days of differentiation identified distinct gene expression profiles in the three treatment groups, we hypothesized that a higher-resolution kinetic analysis would reveal deeper insight into mesendoderm commitment. At 6-h intervals, samples were collected in the three differentiation conditions for the duration of the 48-h time course, and RNA-seq was performed. Whereas E8 and E6 samples clustered randomly, the BA samples all clustered sequentially from 6 to 48 h, as indicated by hierarchical clustering ([Figure 3](#fig3){ref-type="fig"}A; full fold change data in [Table S4](#mmc3){ref-type="supplementary-material"}). This observation is further supported by principal-component analysis, with random grouping of E6 and E8 time points contrasting an ordered trajectory of BA samples in the first two principal component dimensions ([Figure 3](#fig3){ref-type="fig"}B).Figure 3Time Course Transcriptomic Analysis for E8, E6, and BA Samples at 6-h Intervals for 48 h(A) Heatmap of differentially expressed genes, with hierarchical clustering sequentially grouping each BA time point.(B) Principal component analysis showing the E8 and E6 samples clustering together, while the BA samples display an ordered trajectory.(C) Genes differentially expressed in BA samples were clustered into paths based on similarity of temporal expression. Genes comprising each path were analyzed for enriched GO terms for upward trajectories (top row), downward trajectories (bottom row), and a trajectory with upward and downward components (bottom left panel).(D) Enriched GO terms for genes upregulated (top row, red bars) and downregulated (bottom row, blue bars) in BA samples at 12-, 24-, and 48-h time points.(E) List of enriched GO terms for genes upregulated at 48 h in BA samples, with terms related to mesoderm and endoderm differentiation highlighted.

To functionally categorize dynamic gene expression events that regulate mesendoderm differentiation, differentially expressed genes were clustered into discreet paths based on similarity of expression kinetics ([Figure 3](#fig3){ref-type="fig"}C). The unique gene sets comprising each path were then queried individually for enriched GO terms. Genes that were upregulated early but quickly plateaued in expression level (path1) enriched GO terms related to response to growth factor stimulus, such as regulation of SMAD phosphorylation and BMP signaling (full GO analysis can be found in [Table S1](#mmc2){ref-type="supplementary-material"}). Similarly, a query of all genes upregulated in BA after 12 h also enriched terms related to signaling pathways ([Figure 3](#fig3){ref-type="fig"}D). Genes that were upregulated at early time points and continued to be strongly upregulated throughout differentiation (path 2) enriched GO terms related to general differentiation events, such as embryonic morphogenesis, but also more specific terms such as heart development. Genes with expression trajectories that increased at later stages of differentiation (path 3) enriched terms related to specific differentiation events, such as blood vessel development, skeletal system development, and organ morphogenesis. Collectively, analysis of these upward trajectories indicates that transcriptional response to SCS BA induction occurs in waves, whereby cells initially respond to changes in the signaling environment, followed by general differentiation and morphogenesis, and finally specific differentiation events. Genes clustered in paths with a downward trajectory (paths 4, 5, and 6) enriched terms related to nervous system and neural development and differentiation. This enrichment was similar to that observed with query of genes upregulated at 48 h in E6 ([Figure 2](#fig2){ref-type="fig"}B) as well as genes downregulated at 48 h in BA ([Figure 3](#fig3){ref-type="fig"}D). Broader investigation of all significantly enriched biological process GO terms for genes upregulated at 48 h following BA treatment revealed many terms related to specific mesoderm and endoderm cell lineages, including heart development, mesoderm development, blood vessel development, regulation of muscle development, mesenchymal cell differentiation, and endoderm development ([Figure 3](#fig3){ref-type="fig"}E). These data indicate that after 48 h of BA treatment, cells may have the potential to be further instructed to differentiate to a variety of mesoderm cell types, thereby making the SCS BA protocol amenable to a breadth of tissue engineering applications.

Heterogeneous Populations of Mesoderm and Endoderm Cells Are Produced from Initial Single-Cell BA Treatment {#sec2.4}
-----------------------------------------------------------------------------------------------------------

To address the potential for population heterogeneity contributing to transcriptomic analysis, differentiation at the single-cell level was assessed via single-cell qPCR using a 96-gene panel of pluripotency and differentiation markers on the Fluidigm platform ([Figure 4](#fig4){ref-type="fig"}A). Similar to population-level RNA-seq data, cells grown in E8, E6, or BA conditions for 48 h clustered into distinct groups, as revealed by hierarchical clustering analysis ([Figure 4](#fig4){ref-type="fig"}B). Similarly, distinct populations of cells between the three treatment groups were observed on a t-distributed stochastic neighbor embedding (t-SNE) plot ([Figure 4](#fig4){ref-type="fig"}C), suggesting that distinct transcriptional profiles exist for each treatment at the single-cell level. The cluster of genes that distinguished BA cells from E6 and E8 (red box), including *TBXT*, *APLNR*, *GATA6*, *PDGFRA*, *CER1*, *GSC*, and *EOMES*, was enriched for tissues associated with mesoderm and endoderm lineages ([Figure 4](#fig4){ref-type="fig"}D). To assess heterogeneity within the 48-h BA population, co-expression of different combinations of genes within this cluster was visualized ([Figure S2](#mmc1){ref-type="supplementary-material"}). Of 36 BA cells that expressed *PDGFRA*, *TBXT*, *EOMES*, or *GSC*, 6 cells expressed all 4 of these genes at high levels, 11 cells expressed 3 of the 4 genes, 10 expressed 2 genes, whereas only 8 cells expressed only one gene. Co-expression of endoderm genes *SOX17* and *GATA6* with mesoderm marker *PDGFRA* was assessed, revealing that 20 of 22 *PDGFRA*^+^ cells also expressed *SOX17*, *GATA6*, or both *SOX17* and *GATA6*, suggesting that cells express both mesoderm and endoderm markers at this stage. Co-expression of *SOX17* and *GATA6* with additional mesendoderm genes, including *TBXT*, *EOMES*, and *GSC* further supports the mixed expression profile of these cells. Collectively, these data demonstrate that while heterogeneity in gene expression signature exists at 48 h, a significant fraction of cells co-expressed markers of primitive streak and mesoderm and endoderm lineages.Figure 4Single-Cell Gene Expression Analysis(A) Schematic depiction of single-cell gene expression analysis at 48-h and 14-day time points.(B) Heatmap of expression levels of the panel of genes in individual cells after 48 h in E8, E6, or BA. Genes upregulated in BA cells are highlighted (red box).(C) t-SNE plot of individual cells, with E8 cells in blue, E6 in green, and BA in red.(D) Genes in the red box were analyzed for tissue enrichment using EnrichR.(E) Heatmap of expression levels of the panel of genes in individual cells after 14 days. Genes upregulated in BA cells are highlighted in red boxes and genes upregulated in E8 and E6 cells are highlighted in the blue box.(F) t-SNE plot of individual after 14 days (E8 blue, E6 green, and BA red).(G) Genes upregulated in BA cells (red boxes in E) were analyzed for tissue enrichment in EnrichR (top, red bars), as were genes upregulated in E8/E6 cells (blue box in E), bottom graph with blue bars.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

To assess the differentiation potential of cells pre-differentiated in E8, E6, or BA, pretreated cells were allowed to differentiate in basal conditions (E6 or E6 supplemented with B27) for a total of 2 weeks (48 h + 12 additional days). Single-cell analysis of differentiation at the 2-week time point was assessed using the same 96-gene panel as the 48-h time point. Similar to the 48-h time point, BA-treated cells clustered separately from E6 and E8 cells by both hierarchical clustering ([Figure 4](#fig4){ref-type="fig"}E) and t-SNE ([Figure 4](#fig4){ref-type="fig"}F). Interestingly, E6 and E8 samples clustered among each other, suggesting that pre-differentiation in E6 is not sufficient to alter the long-term differentiation trajectory of cells in basal conditions. A number of genes were highly expressed in the BA-treated population and not expressed in the E6/E8 populations, including *HAND1*, *DCN*, *GATA6*, *AQP1*, *ITGB4*, and *DPP4* ([Figure 4](#fig4){ref-type="fig"}E, red boxes), suggestive of mesoderm and endoderm cell lineages. Tissue enrichment analysis for the genes upregulated in 14-day BA cells identified mesoderm and endoderm-derived tissues as most significantly enriched, including lung, kidney, and uterus ([Figure 4](#fig4){ref-type="fig"}G, top). Genes that were highly expressed in E6/E8 samples but not BA samples included *PAX6*, *OTX2*, *ZIC1*, *NES*, *GATA2*, *TUBB3*, *SOX2*, and *OLIG2* ([Figure 4](#fig4){ref-type="fig"}E, blue box), strongly suggestive of a neuroectoderm phenotype. Enriched tissue analysis for these genes upregulated in E6/E8 cells identified largely brain- and ectoderm-related terms ([Figure 4](#fig4){ref-type="fig"}G, bottom). The single-cell gene expression observed is consistent with the dense neurite projections and connectivity that was observed in the E6 and E8 samples, but not BA, after 14 days and indicates that pre-differentiation in E6/E8 allows cells to follow a default trajectory to a neuroectoderm fate. Thus, pre-differentiation in BA is permissive to downstream differentiation to both mesoderm and endoderm lineages but diminishes ectoderm potential.

Pre-differentiation in BA Enhances Chondrocyte Progenitor and Endothelial Progenitor Commitment and Supports Definitive Endoderm Induction {#sec2.5}
------------------------------------------------------------------------------------------------------------------------------------------

Population transcriptomic analysis and single-cell qPCR data demonstrated that SCS BA differentiation produced a cell population with a gene expression profile indicative of mesoderm and endoderm-derived cells, and previous studies have utilized an adapted version of our protocol to produce skeletal muscle progenitor cells ([@bib28], [@bib29]). Therefore, we hypothesized that cells treated for 48 h in BA could be subsequently specified into mature cell types using existing protocols with enhanced efficiency. The cartilage condensation gene set was shown to be significantly enriched after 48-h BA treatment ([Figure 2](#fig2){ref-type="fig"}C), and GO terms related to blood vessel and vasculature development were also found to be significantly enriched following BA treatment ([Figures 3](#fig3){ref-type="fig"}C and 3E). Based on this transcriptomic analysis, existing protocols for chondrogenesis and endothelial progenitor cell (EPC) differentiation were targeted to be modified to include SCS BA pretreatment. For chondrocyte induction, micromass culture ([@bib35]) was adapted to include the 48-h pretreatment protocol in place of embryoid body (EB) formation for H9 hESCs as well as two iPSC lines derived in our lab, as depicted in [Figure 5](#fig5){ref-type="fig"}A. Sulfated glycosaminoglycan (s-GAG) and collagen levels (hydroxy-proline) were quantified after 7 days of micromass culture, and both s-GAG levels and hydroxy-proline expression were significantly higher following BA pretreatment compared with E8 and E6 ([Figure 5](#fig5){ref-type="fig"}B). Proteoglycan production, visualized via Alcian blue staining, was also notably more pronounced in BA-pretreated cells than either E8 or E6 treatments ([Figure 5](#fig5){ref-type="fig"}C). The increase in glycosaminoglycan and collagen production was consistently observed for H9 hESCs and two iPSC lines, demonstrating that SCS BA is amenable to a chondrogenic protocol, and that it is efficacious in robustly enhancing the differentiation of three independent PSC lines.Figure 5Chondrocyte, Endothelial Progenitor Cell, and Definitive Endoderm Differentiation Following BA Pretreatment(A) Schematic depicting the micromass culture protocol utilizing E8 (blue), E6 (green), or BA (orange) pretreatment.(B) Sulfated glycosaminoglycan (left) and hydroxy-proline (right) levels were elevated in BA-treated cells compared with both E6 and E8 in two iPSC lines and H9 hESCs after 7 days of micromass culture.(C) Alcian blue staining for proteoglycan production after 7 days of micromass culture. Scale bar, 2 mm.(D) Flow cytometry analysis of cell surface marker expression after integration of E8-, E6-, or BA-pretreated cells into an EPC differentiation protocol. Isotype immunoglobulin antibody was used as a negative control.(E) Schematic representation of definitive endoderm induction protocol.(F and G) Quantification (F) of SOX17^+^ and FOXA2^+^ cell populations based on immunofluorescent staining in (G). Scale bar, 100 μm.(H) Gene expression analysis of DE genes *SOX17*, *FOXA2*, *GATA6*, visceral endoderm gene *AFP*, and mesendoderm/mesoderm gene *MIXL1*, following the 96-h DE induction protocol.Errors bars represent SEM, n = 3 independent experiments, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001 for (B), (F), and (H). See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

An EPC differentiation protocol ([@bib32]) was similarly modified to include E8, E6, or BA pretreatment in previously derived iPSCs ([@bib6]). To assess EPC differentiation, expression of a number of surface markers was quantified using flow cytometry ([Figure 5](#fig5){ref-type="fig"}D). After 6 days of differentiation, BA-pretreated cells contained a higher proportion of CD31-, CD144-, and VEGFR-2-positive cells than E6 or E8, indicating higher percentages of endothelial cell differentiation. This again demonstrates that the BA population at 48 h can be efficiently directed to different cell types given the proper instructive cues.

Although chondrocyte progenitor and EPC differentiation demonstrate the mesodermal potential of SCS BA-treated cells, we also sought to assay the definitive endodermal (DE) capacity of the SCS BA treatment. Cells initially subjected to 48-h BA treatment (or E8/E6 controls) were subsequently differentiated using E6 medium supplemented with high Activin A (100 ng/mL) with or without the BMP inhibitor LDN193189 (250 nM) ([Figure 5](#fig5){ref-type="fig"}E), based on a previously described protocol ([@bib17]). These experiments suggested that BA concentrations of 10 and 60 ng/mL, respectively, more efficiently induced DE differentiation than 40/40 ng/mL; therefore, 10/60 SCS BA conditions were used for DE induction. After 96 h of DE differentiation, H9 hESCs treated with Activin A alone or Activin A + LDN were \>50% SOX17^+^, indicating a high proportion of DE cells ([Figures 5](#fig5){ref-type="fig"}F and 5G). FOXA2 staining further confirmed the DE phenotype of these cells, as did expression of *SOX17*, *FOXA2*, and *GATA6* genes ([Figure 5](#fig5){ref-type="fig"}H). Expression of the visceral endoderm marker *AFP* was not significantly enhanced following BA pretreatment. *MIXL1* expression in BA-treated cells indicated that a subpopulation of mesoderm cells remains following the DE induction protocol. Similar trends in DE differentiation were observed in H1 and H7 hESCs ([Figure S3](#mmc1){ref-type="supplementary-material"}). Thus, the SCS BA protocol enhances mesodermal differentiation but is also permissive of definitive endoderm commitment; however, higher Activin A and lower BMP4 concentrations support more robust DE induction.

BA Treatment Suppresses Spontaneous and Directed Neuroectoderm Differentiation {#sec2.6}
------------------------------------------------------------------------------

Enriched GO terms for genes downregulated upon BA treatment were frequently associated with neural differentiation ([Figure 3](#fig3){ref-type="fig"}D), and Neural Ectoderm genes were negative for enrichment in GSEA ([Figure 2](#fig2){ref-type="fig"}C). We therefore hypothesized that, after pretreatment in BA for 48 h, cells would be refractory to neural induction. To test this hypothesis, cells treated with E8, E6, or BA were subjected to a common neural differentiation protocol that utilizes dual SMAD inhibition via treatment with LDN193189 and SB431542, inhibitors of BMP and TGF-β, respectively ([@bib5]). After 48 h of pre-differentiation, medium was replaced with either E6 alone, or E6 containing LDN and SB and cultured for a further 3 days ([Figure 6](#fig6){ref-type="fig"}A). At the 48-h time point, cells treated with E8 or E6 expressed SOX2 (80% and 88%, respectively), while BA cells showed virtually no expression (2.5% SOX2^+^; [Figures 6](#fig6){ref-type="fig"}B and 6C). Cells treated with E8 expressed high levels of *OCT4*, *NANOG*, and *SOX2* transcripts at the 48-h time point ([Figure 6](#fig6){ref-type="fig"}D), confirming that these cells remain in a pluripotent state, whereas the E6 treatment resulted in high expression of *SOX2* and *OTX2* with reduced *OCT4* and *NANOG*, suggesting a loss of pluripotency and early neuroectoderm commitment ([Figure 6](#fig6){ref-type="fig"}D). Mesendoderm commitment of BA-treated cells was confirmed, as TBXT was expressed exclusively in BA-treated cells ([Figure 6](#fig6){ref-type="fig"}B), consistent with [Figure 1](#fig1){ref-type="fig"}E. In addition, the loss of *NANOG* and *SOX2* expression along with high expression levels of *OCT4* and *MIXL1* further confirm mesendoderm commitment of BA cells at 48 h ([Figure 6](#fig6){ref-type="fig"}D). Following 5 days of differentiation in both E6 and dual inhibition, pluripotency was lost in all conditions, because a total abrogation of *OCT4* and *NANOG* expression was observed ([Figure 6](#fig6){ref-type="fig"}D). High levels of SOX2 expression (both protein and transcript) in E8 and E6 samples was observed, whereas significantly lower SOX2 expression was observed for BA samples in both types of media ([Figures 6](#fig6){ref-type="fig"}B and 6D). Similarly, the intermediate filament protein Nestin was expressed significantly higher in E8- and E6-pretreated cells in both E6 and dual inhibition media. Spontaneous neuroinduction (E6) was nearly absent in BA-pretreated cells (1% SOX2^+^, 9% Nestin^+^), while significantly lower directed neuroinduction (dual inhibition) was observed compared with E8 or E6 pretreatment. Expression of neural differentiation genes, including *SOX2*, *PAX6*, *OTX2*, and *NES* was extremely low for BA pretreatment in either E6 or dual inhibition media. Finally, BA-pretreated cells allowed to spontaneously differentiate in E6 expressed high levels of *AFP* and *KDR*, demonstrating differentiation of mesendoderm-derived lineages.Figure 6Pretreatment with BA for 48 h Repressed Neuroectoderm Potential(A) Schematic depicting the neuro-induction protocol using E8-, E6-, or BA-pretreated cells as the input population.(B and C) Quantification (B) and representative images (C) of immunofluorescent staining for SOX2 and TBXT after 48 h, and SOX2 and Nestin after 5 days.(D) Gene expression analysis after 48 h, 5 days in E6, and 5 days in dual SMAD inhibition (DI) medium for E8-, E6-, and BA-pretreated cells. Pluripotency (*OCT4*, *NANOG*, *SOX2*), neuroectodoerm (*SOX2*, *PAX6*, *NES*, *OTX2*), and mesoderm/endoderm (*AFP*, *KDR*, *MIXL1*) genes were assessed.Error bars represent SEM, n = 3 independent experiments, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ‡ = p \< 0.001 for (B) and (D). Scale bar, 200 μm.

Teratomas Preferentially Form Mesoderm and Endoderm Lineages Following BA Treatment {#sec2.7}
-----------------------------------------------------------------------------------

Cells subjected to SCS BA treatment demonstrated efficient induction of mesendoderm after 48 h, enhanced efficiency of differentiation of mesoderm lineages, and reduced capacity for neuroectoderm specification under defined conditions *in vitro*. Thus, we hypothesized that, in an *in vivo* environment that is permissive to the formation of all three germ lineages (i.e., teratoma formation), BA-pretreated cells would preferentially differentiate to mesoderm and endoderm lineages and reduced ectoderm lineages compared with E8 and E6 treatment. To test this hypothesis, cells pretreated with E8, E6, or BA for 48 h were injected into the hindlimbs of *NOD/SCID* mice to induce teratoma formation. After 9--18 weeks of teratoma growth, tumors were excised, fixed, sectioned, and stained with H&E to identify tissue structures, including cartilage and pigmented epithelium ([Figure 7](#fig7){ref-type="fig"}A). The formation of primary germ layers was further assessed via immunofluorescent staining for SOX2 (ectoderm), SOX17 (endoderm), and Desmin (mesoderm) ([Figures 7](#fig7){ref-type="fig"}B and 7C). The ratio of mesoderm and endoderm lineages to ectoderm was calculated for the entire teratoma area of three sections from at least four teratomas for each treatment ([Figure 7](#fig7){ref-type="fig"}D). Cells pretreated with BA formed teratomas with the highest mesoderm + endoderm to ectoderm ratio, while E6 treatment produced the lowest such ratio (p \< 0.05 × 10^6^ versus BA). Treatment with E8 resulted in teratomas with a ratio of ∼2 (1.8 ± 0.3), indicating an equal proportion of mesendoderm and ectoderm lineages. Ratios of 4.4 ± 0.8 for BA and 0.8 ± 0.1 for E6 indicate strong bias for mesendoderm and ectoderm differentiation, respectively. Thus, the 48-h pre-differentiation in BA specifies cells on a differentiation trajectory which, in an *in vivo* environment permissive to formation of germ layers in roughly equal proportions, results in commitment to mesendoderm lineages at the expense of ectoderm formation.Figure 7Analysis and Quantification of Teratomas Formed from E8-, E6-, and BA-Treated Cells(A) H&E staining of teratomas derived from E8-, E6-, or BA-pretreated cells.(B) Immunofluorescent staining of teratoma sections for Desmin (mesoderm), SOX17 (endoderm), and SOX2 (ectoderm).(C) Images from adjacent sections in (B) were merged and the percentage of each germ layer in each teratoma section was assessed.(D) Quantification of the combined mesoderm and endoderm to ectoderm area ratio for teratomas formed from E8-, E6-, and BA-treated cells. For each teratoma, 3 regions at least 150 μm apart were analyzed, and 4 × 10^6^, 5 × 10^8^, and 6 BA teratomas were used.Scale bars, 2 mm. Error bars represent SEM; ^∗^p \< 0.05, ^∗∗^p \< 0.005.

Discussion {#sec3}
==========

In this work we describe a simple, robust method for reproducible mesendoderm induction of human PSCs. Transcriptomic data indicated that the cell population produced at 48 h would be amenable to directed differentiation of cell types including chondrocytes and EPCs, which was confirmed experimentally. We further demonstrated that the levels of BA in the SCS BA protocol could be modified to support integration into a DE differentiation protocol, highlighting the adaptability of the technique.

We demonstrate that SCS of PSCs results in quantifiably more homogeneous spatial cellular distribution compared with colony-based seeding. Colony-based seeding strategies can be problematic for reproducibility for a number of reasons. The size and distribution of seeded colonies is a function of the initial colony size, the degree to which colonies are broken up, and the split ratio. Protocols often note the degree of confluency to target before splitting or starting differentiation, which is an approximate and subjective metric dependent on both initial colony seeding density and colony size. By reducing colonies to a single-cell suspension before seeding and plating a fixed cell density, we avoided the common issues associated with colony seeding and significantly improved the uniformity and reproducibility of spatial distributions. Furthermore, the parameters we use to define our method are quantitative and objective, allowing others to easily replicate the protocol.

Previous work has demonstrated that numerous combinations of growth factors, small molecules, and cytokines can be used to induce mesendoderm differentiation from hPSCs. For example, [@bib36] have used a cocktail consisting of Activin A, FGF2, BMP4, and Ly93092 (termed AFBLy) to induce DE lineages, and variations upon this combination to induce other lineages (e.g., FLyA for endoderm, FLyB for mesoderm; [@bib3]). [@bib17] elucidated the signaling components necessary to induce primitive streak and DE from hPSCs, demonstrating that FGF, BMP, and WNT signaling are required for primitive streak formation. While the studies mentioned above have all utilized monolayer culture, EB-based protocols are also commonly used. EB-based methods for mesoderm induction (cardiac myocytes or chondrocytes) utilize 1 day of BMP4 treatment followed by an additional 2 days of BA and FGF2 treatment ([@bib9], [@bib14], [@bib15], [@bib26]). The specific concentration of growth factors depends on the targeted cell lineage and the cell line used for induction. Definitive endoderm-derived lineages, including pancreatic cells and hepatocytes, can also be produced from EBs using a similar growth factor cocktail, albeit with higher levels of Activin A ([@bib13], [@bib23]).

Our mesendoderm induction protocol shares a number of similarities with these existing methods with notable exceptions. Our findings suggest that endogenous levels of WNT and FGF signaling----or perhaps pathway crosstalk----are sufficient for mesendoderm induction in the presence of BA, such that addition of WNT agonists and FGF2 is not required. Interestingly, the specific concentrations of growth factors used varies greatly between protocols. For example, [@bib33] reported DE induction with both BA concentrations of 50 ng/mL, whereas many other DE protocols use Activin A levels as high as 100 ng/mL ([@bib3], [@bib4], [@bib13], [@bib24]). For induction of mesoderm, much lower levels of both Activin A and BMP4 have been utilized (1--10 ng/mL, depending on the cell line and target lineage) ([@bib9], [@bib14], [@bib15], [@bib26]). In the presence of FGF2 and phosphatidylinositol 3-kinase inhibitor (Ly294002), Activin A alone (100 ng/mL) was sufficient to induce DE induction, even in the presence of BMP inhibitor Noggin, while BMP4 alone (10 ng/mL) was able to induce mesoderm in the presence of Activin A inhibitor SB431542 ([@bib3]). We demonstrate that 40 ng/mL of both Activin A and BMP4 is ideal for mesendoderm induction in our SCS culture method. However, while 40/40 was efficient in inducing mesoderm differentiation, reduction of BMP4 to 10 ng/mL and increase of Activin A to 60 ng/mL was required for high levels of DE differentiation, in agreement with previous findings that gradients of BA specify sub-populations of primitive streak ([@bib14]). In addition, the conditions under which hPSCs are maintained for self-renewal may contribute to how cells respond to differentiation conditions, as a variety of approaches exist for maintenance, including use of feeder cells (MEFs) and Knock Out Serum Replacement (KOSR), MEF-conditioned media, mTESR, and E8, as well as a variety of tissue culture coatings including Matrigel and Vitronectin. Transcriptomic studies indicate that variation between pluripotent cell lines is extensive ([@bib1]) and that much of the variance can be attributed to the lab in which the cells are cultured ([@bib8], [@bib22]), suggesting that PSCs are exquisitely sensitive to culture conditions.

We describe a defined differentiation system for the robust induction of a mesendoderm population. Although many studies focus on identifying conditions to direct differentiation to one specific cell type, we developed a system amenable to the derivation multiple lineages. Furthermore, the BA concentrations in our SCS protocol can be optimized to be integrated into a variety mesoderm- and endoderm-derived cell differentiation protocols.

Experimental Procedures {#sec4}
=======================

Cell Lines and Cell Culture {#sec4.1}
---------------------------

A total of six different human PSC lines were used in this study to test the robustness of the protocols, including H9, H1, and H7 hESCs, and wild-type iPSCs derived from fibroblasts obtained from the Coriell Institute Biobank (GM00969) (chondrogenic assays) or from late EPCs ([@bib6]) (EPC differentiation assays). Retroviral reprogramming was performed in defined conditions as described previously ([@bib6]). PSCs were maintained in E8 medium ([@bib7]) on Matrigel (BD Biosciences)-coated 6-well tissue culture plates, as described previously ([@bib6]). Passaging of hPSCs was done using 0.5 mM EDTA solution as a gentle dissociation agent.

Colony and Single-Cell Seeding and Differentiation {#sec4.2}
--------------------------------------------------

For colony seeding spatial analysis and differentiation, cells were passaged as described above with EDTA and split at 1:3, 1:6, or 1:9 ratios. After overnight colony seeding in E8, the medium was replaced with fresh E8, E6, or E6 with 40 ng/mL BA (R&D Systems or Peprotech). To induce mesendoderm differentiation via SCS, hPSCs were treated with 10 μm ROCK inhibitor Y-27632 (Tocris) for at least 1 h before dissociating cells with TrypLE Express (Gibco) for 5--7 min. An equal volume of E8 containing 15% KOSR (Gibco) was added and the cell suspension before trituration with P1000. Cells were pelleted by centrifugation (180 rcf, 5 min), resuspended in fresh E8 containing 10 μm Y-27632, and a sample was taken for cell counting (Cellometer Auto, 2000; Nexcelom Bioscience). Cells were then resuspended at a density of 1.5 × 10^5^ cells/mL and plated into freshly Matrigel-coated 6- or 12-well tissue culture plates. Seeding densities of 1.0 × 10^5^ to 2.0 × 10^5^ cells/mL were also examined in some experiments. After overnight seeding, E8 medium containing Y-27632 was aspirated and replaced with either fresh E8, E6, or E6 with 40 ng/mL BA, except where different BA concentrations are stated. Cells were allowed to differentiate for 48 h, with medium exchanged after 24 h.

Spatial Analysis {#sec4.3}
----------------

Cells were seeded overnight as colonies or single cells, fixed for 15 min in cold 4% paraformaldehyde (PFA), and washed 3× in PBS. Cell nuclei were staining with Hoechst 33342 (Invitrogen) diluted 1:5,000 in PBS for 10 min. Imaging of fixed and stained cells was performed using the Cellomics ArrayScan VTI (Thermo Fisher Scientific) high-content imaging instrument. For each condition, the entire well was scanned, the spatial coordinates of each cell in the plate were acquired, and analysis was performed as described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

RNA-Seq {#sec4.4}
-------

Extraction of RNA from three biological replicates of time course differentiation in E8, E6, and BA was performed using the Macherey-Nagel Nucleospin kit. Concentration and clean-up of RNA was performed via ethanol/sodium acetate precipitation. Samples were pooled from three biological replicates for full-time course differentiation experiments (replicates were not pooled for t~0~, 24-, and 48-h samples) before library construction and sequencing, which were performed at the McGill University and Genome Quebec Innovation Center using the Illumina TruSeq mRNA stranded prep kit, and HiSeq 2000 sequencer with 50- or 75-bp single-end reads. Description of bioinformatics analysis can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Single-Cell Gene Expression {#sec4.5}
---------------------------

Single-cell gene expression analysis was performed using the Fluidigm system. At each time point (48 h and 14 days), cells were dissociated into a single-cell suspension using TrypLE Express (48 h) or Dispase (14 days). Isolation, RNA extraction, and cDNA synthesis were performed using the C1 system and C1 Single-Cell Preamp Integrated Fluidic Circuit (IFC) system according to the manufacturer\'s instructions. Gene expression analysis of amplified cDNA was performed using TaqMan gene expression assays (Applied Biosystems) in the BioMark HD on 96.96 Dynamic Array IFCs. Probes are listed in [Table S2](#mmc1){ref-type="supplementary-material"}, and description of analysis can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Lineage Differentiation and Analysis {#sec4.6}
------------------------------------

Complete description of chondrocyte micromass, EPC, definitive endoderm, and neural differentiation can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Quantitative Polymerase Chain Reaction {#sec4.7}
--------------------------------------

Gene expression analysis was performed by reverse transcription qPCR using a Roche LightCycler 480. RNA extraction was carried out using the Macherey-Nagel Nucleospin RNA kit, and cDNA synthesis was done using SuperScript II Reverse Transcriptase (Invitrogen) from 1 μg of RNA. qPCR was performed using cDNA diluted 1:100, 10 μM forward and reverse primers, and 1× Roche LightCycler 480 SYBR Green I MasterMix. Primers are listed in [Table S3](#mmc1){ref-type="supplementary-material"}.

Immunostaining {#sec4.8}
--------------

Cells in 6- or 12-well plates were fixed in cold 4% PFA, blocked, and permeabilized in 2% BSA containing 0.01% Triton X-100 for 30 min, and primary antibodies were added overnight at 4°C. Alexa Fluor secondary antibodies diluted 1:200--1:400 were incubated for 1 h at room temperature. Cell nuclei were stained with Hoechst diluted 1:5,000 in PBS for 10 min at room temperature. Imaging was performed using the Cellomics ArrayScan. Primary antibodies and dilutions used are listed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Teratomas {#sec4.9}
---------

Complete description of teratoma formation and analysis can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analysis {#sec4.10}
--------------------

Statistical significance was determined using one-way or two-way ANOVA with Tukey or Bonferroni post-hoc tests using GraphPad Prism software. Three biological replicates were used, except where indicated otherwise.
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